Sensei Biotherapeutics Inc (SNSE)
NGM · Healthcare · Biotechnology
Closing price as of 2026-07-17 · Source: TEK2day Finance
Key Metrics
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-102 and SNS-103, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (4.9M) | (5.0M) | (170.6M) | (18.4M) |
| Net Income | (4.6M) | (4.7M) | (170.2M) | (16.0M) |
| Diluted EPS | $-3.62 | N/A | $-131.45 | $-2.84 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (50.2M) | (37.1M) | (31.7M) | (22.3M) |
| Net Income | (48.6M) | (34.1M) | (30.2M) | (21.1M) |
| Diluted EPS | $-31.60 | $-24.40 | $-24.00 | $-16.72 |